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Trifecta by Medtronic CoreValve Evolut
Valve-in-Valve ImplantationStephan Haussig, MD, Gerhard Schuler, MD, Axel Linke, MD
Leipzig, GermanyA 70-year-old man with a prior aortic valve
replacement was referred because of newly diag-
nosed, severe aortic regurgitation. Three years ago,Figure 1. Valve-in-Valve Implantation: Assessment of Failing SJM Trif
(A) Transesophageal echocardiography: severe, transvalvular aortic regurg
Angiography: severe aortic regurgitation of an SJM Trifecta valve (Online V
(23 mm) positioning and deployment (Online Video 3). (E) Final angiogra
absence of aortic regurgitation (Online Video 3). (F) Pressure curves. Lef
gradientmaximum/mean: 54/36mmHg, diastolic aortic pressure: 51mmH
diastolic aortic pressure: 66 mm Hg. (G) Transthoracic echocardiography (
(Online Video 4). (H and I) Three-dimensional computed tomography (3D-
in the aorta (I) (Online Video 5).
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e82because of severe aortic stenosis. Current echocardiography
revealed valve failure leading to severe, transvalvular aortic
regurgitation (Figs. 1A and 1B, Online Videos 1 and 2).
Since 2010, the Trifecta (Fig. 1C) aortic valve, which is
supposed to open more fully and efﬁciently, and therefore to
perform like a natural heart valve, has been commercially
available in Europe (1). Given the patient’s comorbidities
(pulmonary hypertension, chronic obstructive lung disease,
and redo surgery) and frailty (neurological dysfunction sec-
ondary to Parkinson disease), a transcatheter aortic valve
implantation (TAVI) was discussed with the patient (addi-
tive/logistic EuroSCORE 13%/43%, STS Score 3.5%) for
redo surgery. To the best of our knowledge, this is the
ﬁrst description of a successful 23-mm Medtronic Core-
Valve Evolut (MCV) (Medtronic, Minneapolis, Minnesota)
implantation into a failing Trifecta valve.
Based on the pre-operative computed tomography, the
coronary origin was determined to be high enough and the
aortic bulbus wide enough to accommodate the Trifecta
valve leaﬂets, which were pushed aside by the MCV,
and coronary occlusion did not occur. The TAVI proce-
duredperformed without pre-dilationdwas uneventful
(Figs. 1D and 1E, Online Video 3) with an intended MCV
implantation depth of 8 mm. Post-procedural assessment
conﬁrmed an excellent result after valve-in-valve implanta-
tion, with no evidence of residual aortic regurgitation or
patient-prosthesis mismatch (Figs. 1E, 1F, and 1G, Online
Videos 3 and 4; 3-dimensional reconstruction of the valve-
in-valve construct: Figs. 1H and 1I, and Online Video 5).
The patient reported a signiﬁcant improvement in
symptoms (no angina pectoris, New York Heart Associationfunctional class I to II) in the presence of good CoreValve
Evolut function (mean gradient of 10 mm Hg, no aortic
regurgitation) at 6-month follow-up. This case extends our
current knowledge of valve-in-valve treatment using self-
expanding valves (2). It shows that even high-risk patients
with failing bioprosthetic valves, in which the leaﬂets are
attached to the exterior of the valve stent, can be safely
treated by CoreValve Evolut implantation, given that the
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APPENDIX
For supplemental videos, please see the online version of this article.
